// App-Quantinova.ai

9054 : Response to tyrosine kinase inhibitors in advanced non-small-cell lung cancer with concomitant c-MET overexpression and EGFR mutation.

Researchers

Presenter

  • Na Na Lou

Principal Investigators

  • Yi-Long Wu

  • Jin-Ji Yang

  • Xu-Chao Zhang

  • Qing Zhou

  • Jian Su

  • Hua-Jun Chen

  • Zhen Wang

  • Xiao-Yan Bai

  • Bin-Chao Wang

Medical Centers

  • Guangdong General Hospital, Guangzhou, China

  • Guangdong Lung Cancer Institute, Guangdong General Hospital (GGH) and Guangdong Academy of Medical Sciences, Guangzhou, China

  • Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China

  • Guangdong Lung Cancer Institute, Guangdong General Hospital (GGH) and Guangdong Academy of Medical Sciences, Guangzhou, China

  • Division of Pulmonary Oncology, Cancer Center, Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China

Locations

  • China

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Non Small Cell Lung cancer

Biomarkers

  • Epidermal growth factor receptor

Drug/Treatment

  • Anascorp Centruroides scorpion

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved